Trial Information

Summary: An Open-Label, Phase II, Extension Study of MDX-060 with Gemcitabine in Patients Relapsed or Refractory Hodgkin's Disease Previously Treated in Protocol MDX060-05

You have/your child has been asked to participate in this research study because you have/your child has Hodgkin’s disease and you/your child received either gemcitabine alone or MDX-060 in combination with dexamethasone in Protocol MDX060-05 (IRB #05184) and your/your child’s medical condition worsened or stayed the same.  The study will also evaluate how long response to the treatment lasts and what side effects the treatment causes.  Your/your child’s participation in this study is expected to last approximately 12 to 40 weeks for treatment and 2 years for follow-up.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:39:31 PM